trial

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCTId NCT00330863
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 357 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2011-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
357 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-05
Primary completion
2011-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RisperidoneOlanzapineQuetiapineZiprasidoneAripiprazolePaliperidone

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Nina R. Schooler, PhDStudy Director

Sites

8 total
Los Angeles, United StatesAugusta, United StatesIowa City, United StatesBoston, United StatesFall River, United StatesOmaha, United StatesAlbuquerque, United StatesGlen Oaks, United States

Facts & assertions

4 sourced
Enrollment
357
Phase
PHASE4
Primary Completion Date
2011-01
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Olanzapine
drug
Quetiapine
drug
Ziprasidone
drug
Aripiprazole
drug
Paliperidone
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Nina R. Schooler, PhD
person